Market overview

GTC is a guanidinium salt and strong chaotropic agent that denatures proteins and inactivates nucleases and viruses. It is the core of lysis and binding buffers for DNA and RNA extraction, inactivating sample-collection media, and protein work in research and bioprocessing. Supply runs from the calcium carbide, dicyandiamide and thiocyanate chain, with purified grades made by a small group of European, US and Chinese producers.

The question this report answers
How large is GTC demand after the COVID testing peak, and which producers can supply diagnostic-grade material as molecular testing returns to steady growth?

1. Demand: who uses GTC and where it is growing

Molecular diagnostics extraction and lysis kits are the largest use; North America and China lead consumption (Market Krystal estimate).

Demand by application (share of 2025 consumption, Market Krystal analysis)
– Molecular diagnostics extraction and lysis kits: 45%
– Life-science research reagents (RNA/DNA isolation): 20%
– Inactivating sample-collection and transport media: 15%
– Biopharma processing and protein denaturation: 10%
– Chemical synthesis and other: 10%
Publishers give no percentage split, so shares are Market Krystal estimates from extraction-kit chemistry, testing volumes and producer grade positioning.

Demand by region (share of 2025 consumption, Market Krystal analysis)
– North America: 30%
– China: 30%
– Europe: 25%
– Rest of Asia-Pacific: 10%
– Rest of world: 5%

Where demand grows fastest to 2035
– Molecular diagnostics extraction and lysis kits: Sample-preparation demand is growing again, with QIAGEN Sample technologies sales up 5% to USD 170 mn in Q3 2025 (QIAGEN)
– Inactivating sample-collection and transport media: Use in syndromic respiratory, sexual-health and home-collection testing supports growth near the 6% market CAGR published to 2032 (DataHorizzon Research)
– Biopharma processing and protein denaturation: Cell and gene therapy and mRNA workflows add steady demand for high-purity grades to 2035 (Market Krystal estimate)

2. Supply: who makes GTC and how much

Main producers include Alzchem, Anatrace, BioSpectra and Merck (MilliporeSigma), plus Chinese guanidine salt makers (Alzchem; ASPR; BioSpectra; Merck). Producers do not publish GTC capacity; one US producer was funded to reach 25,000 kg of GTC output in 2021 (ASPR), and Alzchem reports the #1 global position in highly purified guanidine salts for diagnostics and pharma (Alzchem).

Main producers and capacity
– Alzchem (Germany): Pure (>=98.5%) and ultrapure (>=99.0%) grades, Trostberg; #1 global position in high-purity guanidine salts
– Anatrace (Calibre Scientific) (US): Holland, Ohio; 10-fold expansion targeting 25,000 kg GTC (ASPR (US HHS))
– BioSpectra (US): Bangor, Pennsylvania plant
– Merck KGaA (MilliporeSigma) (Germany/US): Synthesis and molecular biology grades, >=98.0% assay (Merck)

Production by region (share of 2025 output, Market Krystal analysis)
– China: 60%
– Europe: 20%
– North America: 15%
– Rest of world: 5%

Trade and supply-demand balance
China exports technical and purified GTC to kit makers worldwide, Europe and the US are partly self-supplied in high-purity grades, and the 2020-2021 shortage led the US to fund domestic capacity (ASPR).

3. Value chain: from feedstock to end market

Dicyandiamide / guanidine base + Ammonium thiocyanate + Energy and purification → GTC → Molecular diagnostics extraction and lysis kits, Life-science research reagents (RNA/DNA isolation), Inactivating sample-collection and transport media

Raw materials
– Dicyandiamide / guanidine base: Source of the guanidinium cation, made from calcium carbide via calcium cyanamide; one Chinese maker lists 40,800 t/yr of dicyandiamide capacity (PharmaCompass) (PharmaCompass)
– Ammonium thiocyanate: Source of the thiocyanate anion; Nouryon raised output at Cologne in 2020 for test-kit demand (Nouryon) (Nouryon)
– Energy and purification: Recrystallisation to low-iron, nuclease-free grades drives cost for diagnostic material (Market Krystal estimate)

Production route
GTC is made by fusing or reacting a guanidine source such as dicyandiamide or guanidine carbonate with ammonium thiocyanate, followed by recrystallisation to reagent or ultrapure grade.

Downstream
Kit makers and reagent formulators dissolve GTC into 4-6 M lysis and binding buffers, transport media and phenol-based isolation reagents sold to clinical labs and research users.

Price, cost and margin
Prices fell from the 2020-2021 shortage peak; margin sits in ultrapure, low-iron grades for kit makers. Feedstock cost is low relative to purification and quality control. Margin sits with suppliers of ultrapure grades with iron limits such as.

Where the chain is tightest
High-purity, documented GTC is the constrained step, as the 2020-2021 shortage showed when US authorities funded a 10-fold expansion at one producer (ASPR).

Who sits where in the chain
– Gtc producer: Alzchem, Anatrace (Calibre Scientific), BioSpectra
– Producer and distributor: Merck KGaA (MilliporeSigma)
– Feedstock supplier: Nouryon, Ningxia Sunnyfield Chemical
– Kit converter: QIAGEN, Thermo Fisher Scientific

4. Market size: what demand, supply and price add up to

Market Krystal preliminary estimate (2025)
Two publishers place GTC at USD 50-125 mn with about 6% growth (Market Research Forecast, DataHorizzon). WiseGuy Reports is an outlier at USD 2.54 bn and appears to cover a broader scope. Market Krystal sets the range between the two consistent publisher figures and checks it against a bottom-up view of extraction-buffer volumes and the 25,000 kg GTC output target funded for one US producer during the pandemic (ASPR). The volume check is indicative because producer capacities and prices are not published. On this basis we use USD 60-110 mn. Confidence grade B: published estimates exist; the volume or price cross-check is partial.

How published estimates compare
DataHorizzon and Market Research Forecast agree on growth near 6% but differ by a factor of 2.5 on size, and WiseGuy Reports publishes a far larger figure with conflicting numbers on the same page. Market Krystal anchors its range to the consistent publishers and checks it against extraction-buffer volumes and documented producer output.

Key figures at a glance (third-party, cited)
– GTC market valued at about USD 125 mn in 2023, forecast at USD 215 mn by 2032 (6.1% CAGR) (DataHorizzon Research)
– GTC market valued at about USD 50 mn in 2025 with about 6% CAGR to 2033 (Market Research Forecast)
– Anatrace was funded to expand GTC output 10-fold, targeting 25,000 kg, with a contract value of up to USD 4.8 mn (ASPR (US HHS))
– Thermo Fisher COVID-19 testing revenue fell to USD 0.33 bn in 2023, cutting full-year organic growth by 6 points (Thermo Fisher)
– QIAGEN Sample technologies sales were USD 170 mn in Q3 2025, up 5% (QIAGEN)

5. Outlook to 2035 and scenarios to 2047

Regulation and substitution
GTC is classed as corrosive and harmful and liberates toxic gas with acids (ECHA); guanidine hydrochloride is the main substitute.

Recent developments among key stakeholders
– Oct 2026: Alzchem reported that its new German nitroguanidine plant started operation in Q3 2026 and that guanidine nitrate capacity is being doubled, strengthening its guanidine chain (Alzchem)
– Nov 2025: QIAGEN reported Q3 2025 Sample technologies sales of USD 170 mn, up 5%, led by consumables used in nucleic-acid extraction (QIAGEN)
– Mar 2024: Alzchem received EUR 34.4 mn in EU ASAP funding to expand nitroguanidine and modernise guanidine nitrate plants at Trostberg (Alzchem)
– Jan 2024: Thermo Fisher reported COVID-19 testing revenue of USD 0.33 bn for 2023, confirming the end of pandemic-scale extraction demand (Thermo Fisher)

What this means for the market
Diagnostic kit makers now buy GTC on quality and documentation rather than availability, which favours Alzchem, BioSpectra and other ultrapure suppliers. Chinese producers compete on price in technical and reagent grades. Buyers should keep dual sourcing, as the 2020-2021 shortage showed how fast extraction chemicals can tighten.

Strategic scenarios to 2047
– Base: Demand grows at about 5-6% a year to 2035 with molecular testing and biopharma, then slows to 3-4% to 2047.
– Constrained supply: A new pandemic or outbreak triggers a testing surge that again outruns high-purity GTC supply, lifting prices and prompting state-funded capacity.
– Technology transition: Extraction-free PCR, magnetic-bead chemistries with guanidine hydrochloride and sequencing-based workflows reduce GTC use per test.
The swing factor for GTC is Outbreak-driven testing surges. Signposts: respiratory testing volumes, QIAGEN and Thermo Fisher sample-prep sales, Chinese GTC export prices, guanidine chain investments, extraction-free assay approvals.

What this report delivers
Annual volume (tonnes) and value (USD) for 2026-2035, segmented by application: Molecular diagnostics extraction and lysis kits, Life-science research reagents, Inactivating sample-collection media, Biopharma processing, Chemical synthesis and other; end use: Clinical laboratories, Research institutes, Biopharma manufacturers, Diagnostic kit makers; region: North America, Europe, China, Rest of Asia-Pacific, Rest of world. Each segment is backed by a producer capacity map, trade data and the Market Krystal estimate log, with scenarios to 2047 and strategic recommendations.